Completed PHASE2 INTERVENTIONAL 1-arm NCT00400673

A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia

Two-Step Remission Induction With Risk-Oriented Consolidation (High-Risk: Allogeneic Stem Cell Transplant; Standard-Risk: Multicycle High-Dose Cytarabine With Autologous Blood Stem Cell Support) for Adult Acute Myelogenous Leukemia

Sponsor: Northern Italy Leukemia Group

Conditions Acute Myelogenous Leukemia

Interventions Two-step remission induction and risk-oriented consolidation

Updated 6 times since 2017 Last updated: Mar 31, 2011 Started: May 31, 2000 Primary completion: Oct 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00400673, this PHASE2 trial focuses on Acute Myelogenous Leukemia and remains completed. Sponsored by Northern Italy Leukemia Group, it has been updated 6 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Northern Italy Leukemia Group

Data source: Northern Italy Leukemia Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bergamo, Italy , Bolzano, Italy , Brescia, Italy , Cuneo, Italy , Mestre, Italy , Milan, Italy , Monza, Italy , Noale, Italy , Palermo, Italy , Torino, Italy and 1 more location